FLZ demonstrates its efficacy in rotenone-induced PD mice by rejuvenating the gut microbiome, alleviating intestinal dysfunction, and curtailing inflammation and permeability through the TLR4/MyD88/NF-κB pathway. The gene discussed is NFKB1; the disease is Parkinson disease.